The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Lisaftoclax combinations in R/R myeloma and AL amyloidosis
Jack Khouri, MD, Cleveland Clinic, Cleveland, OH, discusses the safety and efficacy of the novel BCL-2 inhibitor lisaftoclax in different combinations for patients with multiple myeloma and light chain (AL) amyloidosis. The data showed that lisaftoclax was well-tolerated in both cohorts, with low-grade hematologic adverse events and no major serious adverse events. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
